Industry Perspective on Geriatric Drug Testing

Abstract

Pharmaceutical manufacturers maintain a continued interest in proposals for geriatric drug testing. An industry poll indicates varying levels of activity in clinical testing in geriatric patients and varying types of study designs. Manufacturers appear to be almost uniform in supporting the need for some form of geriatric drug testing. Reviews of the proposals for drug testing guidelines developed by the Food and Drug Administration and American Society for Clinical Pharmacology and Therapy are discussed.